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Abstract
Background: Knowledge of HIV status remains below target in sub-Saharan Africa, especially among men and
adolescents. HIV self-testing (HIVST) is a novel approach that enables unique distribution strategies, with potential to be
highly decentralised and to provide complementary coverage to facility-based testing approaches. However,
substantial gaps in evidence remain on the effectiveness and cost-effectiveness of HIVST, particularly in rural settings,
and on approaches to facilitate linkage to confirmatory HIV testing, prevention, and treatment services. This protocol
describes two cluster-randomized trials (CRT) included within the UNITAID/PSI HIV Self-Testing Africa (STAR) project.
Methods: Two independent CRTs were designed around existing reproductive health programmes in rural Malawi and
rural/peri-urban Zambia. Common features include use of constrained randomisation to allocate health clinic catchment
areas to either standard HIV testing (SOC) or SOC plus community-based distribution of OraQuick HIV Self Tests
(Bethlehem, PA USA, assembled in Thailand) by trained lay distributors selected by the community. Community-based
distribution agents will be trained (3-day curriculum) to provide brief demonstration of kit use and interpretation,
information and encouragement to access follow up services, and management of social harm.
The primary outcome of both CRTs is the proportion of the population aged 16 years and older who tested for HIV within
the 12-month intervention period. Secondary outcomes in both trials include lifetime HIV testing, antiretroviral therapy
(ART) initiation and ART use. Circumcision status among males will be a secondary outcome in Zambia and clinic-level
demand for ART will be a secondary outcome in Malawi. Outcomes will be measured using cross-sectional household
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surveys, and routine data extraction from participating clinics. Costing studies will be used to evaluate the cost-effectiveness
of the intervention arm. Qualitative research will be used to guide distribution and explore reasons for testing and linkage
to onward care.
Discussion: The STAR-Malawi and STAR-Zambia trials will provide rigorous evidence of whether community-based lay
HIVST distribution is an effective and cost-effective approach to increasing coverage of HIV testing and demand for follow-
on HIV services in rural and peri-urban communities in sub-Saharan Africa.
Trial registration: Clinicaltrials.gov, Malawi: NCT02718274, 18 March 2016; Zambia: NCT02793804, 3 June 2016. Protocol
date: 21 February 2018.
Keywords: HIV/AIDS, Self-testing, Malawi, Zambia
Background
Knowledge of HIV status remains low in many parts of
sub-Saharan Africa, particularly among men and adolescents
(aged 10–19) [1]. As a gateway to treatment and prevention
services, HIV testing is key to achieving United Nation’s
(UN) 2020 fast track targets [2, 3]. However, recent
population-based data from Malawi and Zambia show that
the percent of people with HIV (PHIV) who know their sta-
tus is far lower than the 90% benchmark set by the UN, with
only 73% of PLHV in Malawi and 67% of PLHIV in Zambia
aware of their status in 2015 [4, 5]. Despite integration and
decentralisation of facility-based HIV testing services in
antenatal care, tuberculosis clinics and primary care, as well
as community-based outreach to reach remote and
under-served communities, knowledge of status remains
low [6, 7]. To overcome these gaps and achieve the UN test-
ing targets, novel and affordable approaches are needed.
HIV self-testing (HIVST) has potential to increase acces-
sibility to and uptake of HIV testing, particularly among
populations not well-served by existing HTS. In HIVST, in-
dividuals collect their own specimen, conduct their own
test, and interpret their own result. In 2016, the World
Health Organization (WHO) recommended HIVST as a
way to expand HTS services, particularly to high risk and
underserved populations [8]. Early studies in Malawi and
elsewhere have shown HIVST to be acceptable, and that
oral fluid HIVST kits can be performed accurately, espe-
cially when provided with a brief in-person or video dem-
onstration along with instructions-for-use provided by the
manufacturer [9–11].
HIVST may provide more readily affordable and sustain-
able community-based HTS than existing models [12, 13].
Cost-effectiveness was shown for a community-based HIVST
study in urban Malawi [14, 15]. Despite the potential impact
of HIVST, evidence concerning cost-effectiveness for rural
communities is limited. Few data to inform evidence-based
choices between different HTS options for encouraging
timely linkage to confirmatory testing and prevention and
treatment services.
The Unitaid/PSI STAR (HIV Self-Testing Africa) project
was developed to strengthen the evidence base around the
effective use of HIVST in sub-Saharan Africa. STAR in-
cludes the design, implementation, and evaluation of a
variety of HIVST distribution models and post-test linkage
strategies. STAR also promotes the development of regu-
latory and policy environments enabling distribution of
quality-assured HIVST kits. This protocol describes two
CRTs within the STAR project assessing the effectiveness
and cost-effectiveness of community-based HIVST distri-
bution models in Malawi and Zambia.
Study objectives
The overall objective of these trials is to evaluate the
effectiveness of distribution of oral-fluid HIVST kits by
community-based distribution agents (CBDA) on uptake of
HIV testing, including coverage of recent (within 12 months)
and lifetime testing among the population ages 16 years and
older, and on ART initiation. The Zambia study also assesses
the impact of self-testing on men’s circumcision status, and
the Malawi study evaluates differences between arms in link-
age to ART (offered routinely under a “test-and-start” strat-
egy by the Government of Malawi) through extraction of
clinic-level ART initiation data. Formative research, consist-
ing of qualitative studies and discrete choice experiments
(DCEs), will inform the final intervention design, training
materials, social harms definitions. Procedures for reporting
social harms related to the intervention are informed by
qualitative research in each setting. Qualitative research and
DCEs will also be used to maximise preferences for service
configurations offered for testing and linkage, and to under-
stand participant experiences. Costing studies and a
cost-effectiveness analysis of the interventions will also be
conducted.
Specific hypotheses tested by the trials include that
community-based distribution of HIVST kits will increase:
(1) the proportion of the population who have tested
for HIV within the past 12 months;
(2) the proportion of the population who have ever
tested for HIV;
(3) the rate of ART initiations in clinics serving
populations that received HIVST distribution.
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Methods and design
Settings
CRTs will be conducted in rural settings in Malawi
(Blantyre, Machinga, Mwanza and Neno districts) and
rural, urban and peri-urban settings in Zambia (Ndola,
Kapiri Mposhi, Lusaka and Choma districts). (Tables 1
and 2 provide additional information on the study sites).
Study design
Using a parallel arm design, clinics will be randomly allo-
cated either to receive community-based HIVST distribu-
tion in a defined catchment area, or to continue with
usual clinic-based HTS (standard of care [SOC]). Clinic
catchment areas will be randomized rather than individual
testers because the intervention was designed to be deliv-
ered by community-based distributors. Individual-level
randomization would therefore be inappropriate.
In Malawi, 22 rural primary health clinics will be ran-
domized 1:1 to receive the HIVST intervention or SOC.
Within the HIVST intervention arm, CBDAs will also be
randomized 1:1 to provide either referrals to home-based
ART initiation or the usual referrals to the clinic. Each
clinic will contain a pre-defined, concentrated area of im-
plementation, with two villages in each area selected for
the baseline and endline household surveys, respectively.
In Zambia, 12 primary health clinics in 4 districts will
be pair-matched within districts by distance to the district
medical office and catchment area population, and ran-
domized 1:1 to provide the HIVST intervention or SOC.
Intervention and standard of care
Both trials will assess the effectiveness of community-
distributed HIVST on HIV testing uptake using Ora-
Quick HIV Self Tests (Bethlehem, PA USA, assembled
in Thailand) including instructions-for-use translated by
the manufacturer into local languages (Chichewa in
Malawi; and Nyanja, Tonga, and Bemba in Zambia). The
specificity and sensitivity of the test kit in a general rural
population in sub-Saharan Africa will be assessed in sep-
arate studies [16]. HIVST kits will be stored and
Table 1 HIV STAR-Malawi study clinics
District Clinic name Clinic Catchment
Population (2014–2015)
Total HIV tests
(2014–2015)
Percent HIV-positive tests
(Number of positive tests / total tested at clinic 100%)
Allocation
Blantyre (N) Chikowa Health Centre 34,317 4128 8.0% HIVST
Blantyre (N) Dziwe Health Centre 18,430 1794 7.6% SOC
Blantyre (N) Lirangwe Health Centre 27,880 3268 14.4% SOC
Blantyre (N) Makata Health Centre
Lunzu
37,000 3502 6.9% SOC
Blantyre (S) Madziabango Health
Centre
15,000 2281 7.2% HIVST
Blantyre (S) Mpemba Health Centre 23,600 5027 10.9% HIVST
Blantyre (S) Pensulo Health Centre 19,172 706 9.8% SOC
Blantyre (S) Soche Maternity 16,208 784 13.6% HIVST
Machinga Chikweo Health Centre 82,581 6938 6.8% HIVST
Machinga Mangamba Health Centre 22,364 5344 6.1% HIVST
Machinga Mbonechera Health Centre 112,934 1195 7.6% SOC
Machinga Mkwepere Health Centre 19,317 2715 6.6% SOC
Machinga Namanja Health Centre 34,678 3930 6.8% HIVST
Machinga Nayuchi Health Centre 21,582 2642 11.5% SOC
Machinga Ngokwe Health Centre 40,778 7165 5.3% SOC
Mwanza Kunenekude Health Centre 12,085 2758 4.9% HIVST
Mwanza Thambani Health Centre 19,056 2561 5.0% SOC
Mwanza Tulonkhondo Health
Centre
16,700 2261 4.1% SOC
Neno Chifunga Health Centre 11,250 1994 6.0% HIVST
Neno Ligowe Health Centre 15,025 2118 5.0% SOC
Neno Luwani Health Centre 4452 1027 5.3% HIVST
Neno Magareta Health Centre 7547 1550 3.4% HIVST
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distributed by Population Services International (PSI)--
Malawi or Society for Family Health (SFH)-Zambia. In
both trials, CBDAs will be trained by PSI or SFH in how
to explain the written self-test instructions, demonstrate
correct use, and show examples of reactive and
non-reactive tests to assist in reading results. Distributors
will also be trained on appropriate test kit storage and infor-
mation concerning linkage to confirmatory testing and ART
for clients with reactive HIVST results or prevention for cli-
ents with non-reactive results. Clients will be offered the
choice of testing with CBDA assistance or in private. CBDAs
will also be trained in how to pre-empt, respond to and re-
port social harm, including suicide, gender-based violence,
or coerced testing. Individuals are eligible for HIVST if they
are ages 16 years or older.
In Malawi, CBDAs will provide door-to-door community-
based distribution of HIVST kits as well as access from their
own homes, building on a pre-existing initiative providing
reproductive health products. CBDAs will provide all clients
who wish to test with: (1) information on the test and a
demonstration on how to open and use the HIVST kit; (2)
an envelope and short anonymous questionnaire to be com-
pleted by the client and returned with the kit; and (3) a
self-referral form to facilitate linkage into HIV care and pre-
vention services. CBDAs will distribute one test per resident
who is interested in testing. CBDAs will visit clients after dis-
tributing the kit to enquire whether the kit has been used,
collect the sealed questionnaire and used kit, and provide ad-
vice on referral to additional care if the client discloses a re-
active HIVST result. Clients will also be able to drop used
kits in locked boxes within each community, or return them
to CBDAs at their homes.
CBDAs will be paid MWK 100 (USD 0.15) for each
test kit distributed, and an additional bonus (MWK 50,
or USD 0.08) for facilitating onward linkage to health
services for clients with reactive HIVST results.
Malawi – Home-based ART intervention
In a second-stage randomisation, CBDAs working within
clinic catchment areas allocated to the intervention
(HIVST) will be randomly allocated to either no additional
intervention, or HIVST plus the offer of home-based con-
firmatory testing, WHO staging, TB symptom screening
and initiation of HIV care including a 4 week supply of
ART and cotrimoxazole and a government ART patient
card for service continuation at the nearest clinic. HIVST
clients will need to confide their reactive self-test result
with the CBDA, who will then arrange a single home visit
by PSI nurses within seven days. This builds on a success-
ful urban intervention of similar design [17].
Zambia – HIVST intervention
In Zambia, multiple modes of HIVST distribution will
be provided to the catchment population of each inter-
vention facility in addition to a similar CBDA model to
Malawi. Healthcare workers will distribute HIVST
within health facilities, while CBDAs will visit house-
holds to dispense HIVST kits. Voluntary male medical
circumcision (VMMC) mobilizers employed by PSI are
associated with some but not all facilities, and in inter-
vention areas will distribute self-test kits as part of their
activities. Distribution modes for each clinic are listed in
Table 3. As in Malawi, clients who agree to HIVST will
receive a demonstration of kit use; an envelope for the
used kit and anonymous self-complete questionnaire to
return with kit; and a self-referral card to the health fa-
cility to assist with linkage to confirmatory testing and
care as needed. Boxes to return used self-test kits will be
located at each facility as well as in public areas in the
community, and used kits can be returned to CBDAs.
CBDAs will be recruited from the communities in
which they will work, and will have previously worked
with the health facilities included in the impact evaluation.
Table 2 HIV STAR-Zambia study clinics
Pair District Community Type of community
(rural/peri-urban)
Distribution models Population (2016) Distance to district medical
office in km
Allocation
1 Choma Mbabala Rural Community, facility, VMMC 11,415 33 HIVST
1 Choma Mapanza Rural Community, facility, VMMC 14,528 75 SOC
2 Choma Batoka Rural Community, facility, VMMC 15,566 33 HIVST
2 Choma Sikalongo Rural Community and facility 13,491 66 SOC
3 Kapiri Mphoshi Chankomo Rural Community and facility 15,228 55 SOC
3 Kapiri Mphoshi Nkole Rural Community, facility, VMMC 15,365 34 HIVST
4 Kapiri Mphoshi St Pauls Rural Community and facility 7673 90 SOC
4 Kapiri Mphoshi Mpunde Rural Community, facility, VMMC 15,694 48 HIVST
5 Lusaka Ng’ombe Peri-urban Community, facility, VMMC 45,999 8 HIVST
5 Lusaka Makeni Peri-urban Community and facility 51,264 9 SOC
6 Ndola Lubuto Peri-urban Community, facility, VMMC 53,249 8 SOC
6 Ndola Twapia Peri-urban Community, facility, VMMC 24,078 9 HIVST
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CBDAs and VMMC mobilisers will be paid using a
performance-based structure (ZMW 5/distributed kit and
ZMW 2.5/used kit returned, or USD 0.56 and 0.28).
Standard of care (SOC)
In facilities allocated to the SOC arms, health facilities
will provide HIV testing and ART initiation as dictated
by national guidelines. In Malawi, pre-existing repro-
ductive health CBDAs will continue providing services
in standard of care areas.
Trial participants and procedures
The trial flow charts (Figs. 1 and 2) illustrate the recruit-
ment processes used during the two CRTs. In Malawi,
all clinics offering ART in the study districts were eli-
gible for inclusion. In Zambia, there were 109 clinics in
four districts where HIVST would be distributed. Clinics
hosting other HIV-related programs or that did not offer
ART were not eligible for inclusion. Clinics were
matched based on size of population served and, for
peri-urban sites, distance from urban centre.
Data collection
Repeated cross-sectional surveys will be used to evaluate
the effectiveness of the intervention. Household survey data
will be collected at baseline, before the intervention starts,
and after at least 12 months of intervention delivery.
Household surveys also include DCEs and questions on
costs of testing for use in economic analyses. Contents of
the baseline and endline surveys are online at: http://hiv-
star.lshtm.ac.uk/protocols/). In addition, process data on
the number of tests distributed and used will be collected
from individuals accepting HIVST by CBDAs and in ques-
tionnaires completed by clients themselves. Qualitative data
will be collected for formative research and process evalua-
tions. Table 4 provides an overview of data collected for the
STAR-Malawi and STAR-Zambia impact evaluations.
Malawi – Survey data collection
Evaluation data will be collected from selected villages
within the implementation area of each clinic (Fig. 3). Eligi-
bility requirements for the evaluation villages will include:
 Location within the catchment area of an eligible
ART clinic, with the clinic acting as the most
dominant source of ART for the village.
 Presence of at least one active reproductive health
CBDA prior to the study period.
 Population of at least 250 adults per village.
 Road access for most/all of the year.
 Sufficient distance and separation from
administrative boundaries and other intended
evaluation villages to minimise contamination
between HIVST and control villages and missed
linkage events from seeking HIV care at a clinic not
included in the evaluation.
 Village delineation by natural boundaries (e.g.,
rivers, roads, forests, etc.)
Within evaluation villages, all households will be enumer-
ated and a variable fraction will be surveyed to ensure that
approximately 300 individuals within households will be in-
cluded. Within selected households, all eligible household
members ages 16 years and older will be surveyed with a
short questionnaire including sociodemographic, testing,
and sexual behaviour, and 20% of surveyed individuals will
receive an extended questionnaire with added questions on
HIV care and questions for economic evaluation. Baseline
and endline surveys will be administered in different com-
munities within each clinic catchment area.
Zambia – Survey data collection
Evaluation data will be collected from an area outlined
using a radius of approximately 3.8 km around a central
point within the intervention and control areas. Within
this area, blocks of 20–30 households will be defined using
mapping software and numbered in a spiral sequence.
Table 3 Primary and secondary outcomes of HIV STAR-Zambia and HIV STAR-Malawi impact evaluations
Outcome Trial Data source
Primary outcome – community HIVST distribution
Tested for HIV within past 12 months Malawi, Zambia Self-report, endline household survey
Secondary outcomes – community HIVST distribution
Ever tested for HIV Malawi, Zambia Self-report, endline household survey
ART initiation 6 months and 12 months after distribution begins Malawi, Zambia Routine data extracted from clinic
Current ART use Zambia Self-report, endline household survey
Circumcision within past 12 months (men only) Zambia Self-report, endline household survey
Primary and secondary outcome – home-based distribution (Malawi only)
Primary: Disclosure of a positive results to the CBDA during months 1 to 12 of intervention Malawi CBDA post-test log book
Secondary: ART initiation between months 1 and 12 of the intervention Malawi Routine data extracted from clinic
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Blocks to be visited at baseline will be determined using a
random number generator. Within each randomly selected
block, all households will be visited and all eligible house-
hold members ages 16 years and older asked to participate
in the household survey. An independent sample of blocks
will be generated for the baseline and endline surveys.
Power calculations for survey data
Malawi
The survey sample size was calculated to ensure suffi-
cient power to identify a difference in the primary out-
come between the HIVST intervention and standard
care arms for the first stage randomization. The calcula-
tion accounts for clustering by incorporating the cluster
coefficient of variation (k) using methods outlined in
Hayes and Moulton [18]. The average cluster size was
estimated to be 250–500 individuals, which is the typical
size of a rural village based on previous experience
working in Malawi, and a sample of 250 participants per
cluster was used for the sample size calculations. We as-
sume that the cluster coefficient of variation (k) was
0.25. Using 2010 Demographic and Health Surveys
(DHS) data, the baseline proportion of adults tested in
the last 12 months was estimated at 25% to 40% and
ever tested at 42% to 60%. Using these assumptions, 11
clusters per arm will allow us to have 80% power to de-
tect a 30% relative difference in recent HIV testing and a
45% relative difference in lifetime HIV testing between
arms of the first stage randomization with α = 0.05.
Zambia
As in Malawi, the survey sample size was calculated to
ensure sufficient power to identify a difference in the
primary outcome between those receiving the HIVST
intervention and those receiving standard care, and uses
similar methods. We estimated that the cluster coeffi-
cient of variation (k) was 0.2, and that cluster popula-
tions were larger than in Malawi. Using 2013–2014 DHS
data, baseline rates for adults tested in the last 12 months
is estimated to be between 28.6–57.1% (lower in men
than women). For this sample calculation, we will as-
sume a testing rate of 50% in the standard of care arm.
For a two-sample comparison of matched proportions
across 6 pairs of matched communities, we will have
80% power to detect a 50% relative difference in recent
HIV testing if we recruit around 400 respondents per
community, or 4800 respondents in total.
Fig. 1 Flow chart, HIV STAR-Malawi
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Table 4 Overview of data collected for HIV STAR-Malawi and HIV STAR-Zambia impact evaluations
Data type Data collected
Pre-intervention During intervention period 12 months after intervention begins
Household survey • Ever tested
• Tested within past 12 months
• Current ART use
• Self-reported circumcision status
• Ever tested
• Tested within past 12 months
• Current ART use
• Self-reported circumcision status
Clinic data extraction ART initiations from each study
clinic by sex, age, self-testing status
CBDA M&E data • Number of kits distributed
• Sex and age of persons receiving kits
• Barcode on test kit to link with returned kit
Client-returned kit • Used test kit
• Self-completed questionnaire with test
result, client sex, age
• Barcode linking to CBDA M&E data
Qualitative data • Situational analysis and community
mapping (ZM, MW)
• Cognitive interviewing on IFUs (ZM, MW)
• Formative research on attitudes and
preferences toward self-testing (ZM)
• Process evaluation (ZM)
Economics data • DCEs to understand preferences for
testing and linkage
• Costs of health facility based HIV
testing at baseline
• Costs of HIV testing, including
self-test distribution models
Fig. 2 Flow chart, HIV STAR-Zambia
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Randomization
The Malawi trial includes two stages of randomization. In
the first stage, clinic catchment areas will be allocated to
HIVST or standard of care arms using restricted
randomization. To ensure that intervention and standard of
care clinics are evenly distributed geographically across the
study area, we will restrict the number of intervention
clinics in each district, with larger districts to include at least
35% intervention clinics. We will balance arms in terms of
number of testers, proportion of positive tests, and total
catchment population across clinics. The study statistician
(MN) provided a list of 1000 eligible randomization combi-
nations to the study team and the final randomization
scheme was selected in a public ceremony in Blantyre,
Malawi on 21 March 2016.
In the second-stage randomization, we will randomize
all CBDAs providing HIVST to home-based initiation of
ART or standard of care at a 1:1 ratio. CBDAs will be
randomized in blocks of varying sizes from 2 to 12
CBDAs, with the distribution of block sizes following
Pascal’s triangle (i.e., 1:5:10:10:5:1).
In Zambia, clinics will be randomized 1:1 within
matched pairs to receive the HIVST intervention or
standard of care. Randomization was conducted by the
statistician (BH) and was completed on 24 June 2016.
Outcome evaluation and measurement
HIVST intervention
The primary outcome of the HIVST evaluation in both
Malawi and Zambia is the proportion of village residents
(16 years and above) who tested for HIV within 12 months
after the beginning of the intervention period. Outcome
data (numerators and denominators) will be collected dur-
ing an endline household survey.
Secondary outcomes for the Malawi study include the
proportion who report ever HIV testing, and the propor-
tion initiating ART at clinics for participant residents in
evaluation areas during months 1 to 12 of intervention.
Outcome data (numerators and denominators) for ever
testing will be collected during an endline household
survey. ART initiation data will be extracted from clinic
records at 3-month intervals, and the allocation status of
each individual in the clinic records will be ascertained
using the client’s village of residence. Denominator data
will be village adult population counts.
Secondary outcomes for the Zambia study include re-
ported HIV testing during the intervention period, reported
lifetime testing for HIV, self-reported current ART use,
ART initiation, and self-reported recent circumcision for
men. Data to measure these HIV testing, current ART use,
and recent circumcision will be collected in the household
endline survey. ART initiation will be measured using rou-
tine facility data on ART initiations.
Malawi – Home-based ART intervention
The primary outcome for the second-stage randomisation
of CBDAs to home-based initiation or clinic referral will
be the number of participants (16 years and older) disclos-
ing a positive result to the CBDA during months 1 to 12
of the intervention. Status disclosure is captured through
returned self-completed questionnaires by the CBDAs.
The secondary outcome for this second-stage random-
isation will be ART initiation rates for participants
(16 years and older) during months 1 to 12 of interven-
tion. Data to measure ART initiation will be collected in
two different ways: for the HIVST testing intervention,
data will be extracted from routine facility ART records as
for Zambia. For the home-initiation versus facility-
initiation linkage intervention, ART initiations will be
identified through collection of “self-referral forms” pro-
vided to all clients that include CBDA identification
information and data on the type of HIV care received. In
the SOC arm, self-referral forms will be collected from
health facilities. In the home-based-initiation arm, self-
referral forms are collected from health facilities or the
study nurse providing HIV care at home. Counts of
self-referral forms will be compared to calculate differ-
ences in ART uptake across arms.
Fig. 3 Diagram of Malawi clinic area
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Blinding
Because of the nature of the interventions, neither cli-
ents, distributors nor data collectors, will be blinded to
the allocation status. However, analyses will be con-
ducted on data with identification arm allocation re-
moved, and the trial statisticians (MN, KF, BH) will be
un-blinded only after data have been finalized.
Data management
Quantitative data will be captured using electronic devices
(tablets). In Malawi, program data will be extracted onto
optical character recognition forms and processed into a
dedicated database. Incoming electronic data will be
checked regularly for errors, with supplemental training
provided to field staff if required. All quantitative data will
be cleaned and analysed using Stata 14 or 15 [19]. All par-
ticipants will be assigned a study ID number. Their names
will not be linked except through paper-based recruitment
logs, which will be stored in locked cupboards. Similarly,
in Zambia, quantitative client-level program data will be
captured using electronic devices by CBDAs onto a plat-
form based on Open Data Kit (ODK), an open source
platform that allows for data collection through the use of
mobile devices in real time and offline. From the CBDA,
data will be uploaded to a central computer at SFH Head
Quarters via the internet on a weekly basis, and data will
be password-protected to ensure confidentiality. No client
names will be collected, with linkage of client data instead
using barcoded unique identifiers.
Qualitative data will be recorded in two forms – observa-
tional notes and digital audio recordings – and cross-refer-
enced for accuracy. The audio file will be transcribed
verbatim, and then will then be translated into English. All
data will then be transferred to and coded using a qualita-
tive data analysis software package, such as NVivo 10 [20].
As described elsewhere [21], data on costs will be ex-
tracted from project, PSI, and Ministry of Health records of
expenditure including transport and training, unit costs,
and salaries. Time and motion studies will be used to esti-
mate the proportion of time spent on HTS by staff with
multiple duties. Patient direct and indirect costs incurred to
access HIV testing will be identified by interview at base-
line, and for HIVST by interview at endline, surveys. Anon-
ymized data will be made available in a public repository
after the project is completed and findings disseminated.
Fidelity of intervention and process evaluation
Quantitative monitoring and evaluation will be used to-
gether with qualitative process evaluation data to assess
the following questions:
 Have HIVST kits been distributed in
communities, and to whom? This will be assessed
quantitatively using monitoring and evaluation data
collected by CBDAs, as well as information provided
by clients on the self-completed questionnaire
returned with the used test kit. This will be used to
assess the volume of distribution in different areas
and demographics of recipients, and whether these
characteristics changed over time.
 Have people in the intervention communities
received and used HIVST kits? This will be
assessed quantitatively using the self-completed
questionnaire returned with the used test kit and the
endline household survey by asking whether house-
holds were visited by CBDAs and received HIVST
kits. These data will examine whether the interven-
tion reached the expected population. Households in
both intervention and SOC arms will be asked about
CBDA visits to assess contamination.
 Do potential test users know how to receive care
or prevention services? This will be assessed within
the household survey at baseline and endline, and
will be important for understanding whether clients
could link to additional care following testing.
 Would test users recommend self-testing to their
family or friends? This will be assessed within the
endline household survey, and will be used to
understand whether self-testing was a generally
positive experience.
A qualitative process evaluation will also be conducted
for each impact evaluation, following up on the issues
described above. Qualitative research related to the trial
is discussed in greater detail below.
Reporting of social harms and adverse events
While HIV testing programs are well-established in
these settings, concerns remain about the possibility of
HIVST leading to harmful reactions from self-testers,
their partners, or their families. We will assess social
harms (including all forms of gender-based violence, any
physical injury or related hospitalization and death due
to assault) related to the self-testing intervention using a
community reporting system established in each study
cluster. Adverse events (AE) and serious adverse events
(SAE) will be monitored for both trials.
In Malawi, social harm and AEs disclosed by clients to
CBDAs will be recorded and followed up by PSI staff and
local researchers. Active community-based reporting sys-
tems, with members pre-identified through social map-
ping, will also be established in the evaluation villages to
report social harms. In Zambia, social harm and AEs will
be tracked within a reporting system including CBDAs,
local health clinics, community leaders and CBDA super-
visors. CBDAs will be asked to follow up with clients ex-
periencing serious events related to HIVST as well as any
action taken. AEs will be categorized by severity, with
Neuman et al. BMC Public Health         (2018) 18:1234 Page 9 of 12
SAEs including death, hospitalization, or violent assault
within 30 days of a reactive HIV self-test. SAEs will be re-
ported immediately to the principal investigator, while
other AEs will be logged and reported regularly to the
study team and technical advisory group (TAG).
In addition, we will use questions within the household
survey on recent testing experiences to assess whether any
HIV tests were coerced, whether clients regretted testing
at the time of the test or at the time of the survey. These
questions will be asked for all recent HIV tests, including
both HIVST and standard HTS. We will also ask women
participating in the survey about experiences with IPV at
baseline and endline. Finally, we will assess the prevalence
of perceived HIV-related stigma in the community at
baseline and endline, to assess whether these beliefs
change as a result of the intervention.
Trial analysis
All analyses will be completed in Stata 14, on an
intention-to-treat basis, and will use methods appropri-
ate for CRTs with a small number of clusters [18].
Reporting will conform to the 2010 CONSORT state-
ment as applicable to cluster randomized trials [22].
Analyses will be conducted separately by country. Ini-
tial analyses will compare characteristics of households
and respondents across arms at baseline. These baseline
analyses will be completed before analysis of endline
data begins. Characteristics of households and respon-
dents at endline will be summarized by arm, so that im-
balances can be accounted for in our final analysis.
Missing data will be examined for each variable and for
each cluster or individual participant. A systematic assess-
ment of missingness will be conducted to ascertain the
reason and possible mechanism for missing data by identi-
fying the quantity of missing data and patterns within the
data. Missingness will be examined by cluster and between
randomised arms to assess for systematic biases.
Primary and secondary trial outcomes will be com-
pared using cluster-level unadjusted and adjusted means
of recent testing. The analysis will give each cluster
equal weight. For the unadjusted analysis, the overall
prevalence of the outcome for each cluster will be calcu-
lated, and a log transformation will be applied to the
prevalence for each cluster if needed. If there are any
clusters with no events, one event will be added to all
clusters so that the log transformation can be conducted.
The mean and standard deviation of the log prevalence
will be used to obtain the geometric mean and associ-
ated 95% confidence intervals for each trial arm.
For the adjusted analysis, a two-stage approach will be
used. First, a logistic regression model including individual-
level adjustment factors but not trial arm will be fitted, and
predicted probabilities from this model used to estimate
the ratio of observed to expected outcome events for each
cluster. This ratio will be log transformed, and a t-test of
the difference between logs by arm will be used to estimate
the prevalence ratio, 95% confidence interval, and p-value.
For both unadjusted and adjusted analyses, we will report
risk ratios and risk differences. If adjustment for cluster-
level factors is considered necessary, this will be conducted
at the second stage using linear regression of the log ratio
of observed and expected values on arm and cluster level
factors, with appropriate adjustment for the degrees of
freedom. The adjusted analysis will serve as the primary
analysis of each trial. Sensitivity analysis for the primary
outcome of recent test for HIV will be carried out by com-
paring complete case analysis results with those where
missing outcome status are re-classified as yes and no.
Economic analyses
Costing and cost effectiveness studies
The costing analysis will estimate the societal-level costs
of community distribution of HIVST, both from the per-
spective of the health provider and the user, and will
compare the costs of community HIVST distribution
with standard HTS. The costing study will feed into esti-
mates of cost-effectiveness, which will be projected on
different time scales and population levels.
Full financial and economic costs from the providers’
perspective will be collected from PSI/SFH and from
public health care facilities. User costs of accessing exist-
ing and new forms of HIV testing and linkage to care
will be gathered using the extended baseline and endline
questionnaires. Costing tools will be used in conjunction
with service-related financial and activity reports in
order to determine the unit costs of providing HTS and
subsequent HIV care. We will also carry out detailed
micro-costing, including time and motion studies, to
clinics assigned to the intervention and control arms of
the impact evaluation. This will help to identify in-
stances of reduced crowding in ART clinics due to
HIVST decentralisation. Gathered costing data will be used
to conduct an economic evaluation, using decision-analytic
modelling, to compare the costs of the different HIVST
models to standard HTC models. Key outcomes will in-
clude the incremental cost per Disability Adjusted Life-Year
(DALY) averted, which will allow the cost-effectiveness of
HIVST and linkage to care models to be determined.
Discrete choice experiments
This study will administer two DCEs within baseline house-
hold surveys in Malawi and Zambia to inform HIVST im-
plementation strategies. The first DCE will investigate
preferences regarding delivery of HIVST relative to
standard-of-care HTS, while the second DCE will evaluate
preferences for linkage to onward HIV testing and care ser-
vices [8]. We will sample approximately 500 participants
for each DCE to allow for analysis of relative strength of
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preferences among the general population as well as among
key sub-groups such as men and adolescents [23]. Partici-
pants will be randomly allocated to one of the two DCEs.
We estimate HIV prevalence of 8.8% and 13% respectively
in Malawi and Zambia [24, 25]. Respondents reporting
HIV positive statuses were administered the linkage DCE.
To elicit meaningful responses, the interviewer will present
the HIV self-test kit to respondents and demonstrate the
self-testing process at the beginning of the DCE.
Our analysis will include a simple multinomial logit
and more complex choice models, such as mixed multi-
nomial logit, latent class model and generalized multi-
nomial logit model, to explore preference heterogeneity
[26]. Socio-demographic characteristics and HIV-related
experience will be explored to understand how they may
influence respondents’ preferences.
Qualitative research
Qualitative research related to the CRTs will include both ex-
ploratory and explanatory research as well as triangulation of
findings across quantitative and qualitative methods. In the
initial formative phase exploratory research will include an
analysis of preferred self-test distribution models by age and
sex to create an understanding of the concerns and prefer-
ences of various typical testers or ‘archetypes’. Results from
preliminary analysis will be communicated to and discussed
with implementers designing communications and market-
ing strategies as well as distribution models to shape delivery
of self-tests. The formative research will also identify defini-
tions and interpretations of harm among anticipated users,
enabling us to better understand language around harm and
coercion and to report harms using locally understood defi-
nitions. In-depth interviews with participants from the target
populations will assess users’ cognitive understanding of in-
structions for use and ability to conduct tests, enabling us to
develop support materials that optimise HIVST perform-
ance. Findings from these ‘cognitive interviews’ will also
underpin the development of a training curriculum for dis-
tributors that addresses community concerns, demonstrates
correct use of kits, and supports onward linkage. Finally, key
informant interviews will be used to identify processes for
and barriers to regulation of HIVST by national govern-
ments. As the study progresses we will undertake additional
interviews with individuals and communities who have used
HIVST to describe their experiences and help to probe be-
haviours around uptake, linkage, and coercive testing.
To facilitate cross-country qualitative research, we will es-
tablish an inter-country network of qualitative researchers
(the qualitative research network) in STAR. This will allow
for a robust analytical approach to the inter-country ana-
lysis of the qualitative findings that is interactive, collabora-
tive and rooted in a strong understanding of the local
contexts. Common data collection tools, sampling and cod-
ing frames will be developed iteratively through multiple
rounds of joint discussion and analysis will thus feed into
and be informed by the larger trial as an essential part of
trustworthiness. We will use a framework approach to our
qualitative analysis that will allow for both deductive and
inductive themes to be captured and inform the larger trial
at various stages as outlined above.
Trial management
The trials will be overseen by an independent TAG, com-
posed of up to six members who will be experts in research,
health systems, policy, human resources and community
health. The TAG meets semi-annually to review summaries
of survey and monitoring and evaluation data, review any
reports of severe adverse events or other social arms, and
to assess the progress of these impact evaluations and other
STAR research projects more generally. Both impact evalu-
ations are short, pragmatic evaluations, and HIV self-testing
is an established intervention. We do not expect substantial
harms to result from the intervention, and will not establish
a separate data safety monitoring board..
Interim analysis and stopping rules
Interim survey data will be collected in intervention loca-
tions only to assess uptake of the intervention. These data
will be collected between 4 and 6 months after the begin-
ning of the intervention. Summaries of process and survey
data will also be reviewed by the TAG. Frequencies of key
process and outcome indicators will be distributed intern-
ally and to the donor. Because the intervention period will
be brief and because we expect that there will be no sub-
stantial adverse impacts of the intervention, we will not
establish a stopping rule for either study..
Discussion
The STAR-Malawi and STAR-Zambia trials will provide
rigorous evidence of whether community-based HIVST
distribution is effective at increasing HIV testing uptake in
rural and peri-urban communities in sub-Saharan Africa.
Results from both CRTs and other STAR research will be
used by local ministries to develop plans for self-testing in
national HIV testing plans, and will be integrated into up-
dated guidance for implementation of HIVST programmes
by the WHO and other international organizations.
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